MX2015016102A - Metodos para la liberacion de cromolina. - Google Patents

Metodos para la liberacion de cromolina.

Info

Publication number
MX2015016102A
MX2015016102A MX2015016102A MX2015016102A MX2015016102A MX 2015016102 A MX2015016102 A MX 2015016102A MX 2015016102 A MX2015016102 A MX 2015016102A MX 2015016102 A MX2015016102 A MX 2015016102A MX 2015016102 A MX2015016102 A MX 2015016102A
Authority
MX
Mexico
Prior art keywords
methods
cromolyn
delivering
delivering cromolyn
aliergic
Prior art date
Application number
MX2015016102A
Other languages
English (en)
Inventor
Franzusoff Alex
R Elmaleh David
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of MX2015016102A publication Critical patent/MX2015016102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con métodos para liberar cromolina a un paciente en necesidad del mismo, métodos de tratamiento de las afecciones amiloideas asociadas y enfermedades inflamatorias o alérgicas pulmonares y empaques de burbuja y kits que comprenden cromolina.
MX2015016102A 2013-05-23 2014-05-22 Metodos para la liberacion de cromolina. MX2015016102A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361826798P 2013-05-23 2013-05-23
PCT/US2014/039118 WO2015002703A1 (en) 2013-05-23 2014-05-22 Methods for delivering cromolyn

Publications (1)

Publication Number Publication Date
MX2015016102A true MX2015016102A (es) 2016-08-08

Family

ID=52144109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015016102A MX2015016102A (es) 2013-05-23 2014-05-22 Metodos para la liberacion de cromolina.
MX2020013362A MX2020013362A (es) 2013-05-23 2015-11-23 Metodos para la liberacion de cromolina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013362A MX2020013362A (es) 2013-05-23 2015-11-23 Metodos para la liberacion de cromolina.

Country Status (9)

Country Link
US (1) US9861608B2 (es)
EP (1) EP2999337A4 (es)
JP (3) JP2016534976A (es)
CN (2) CN110652495A (es)
AU (4) AU2014284656B2 (es)
CA (1) CA2913235C (es)
HK (1) HK1218050A1 (es)
MX (2) MX2015016102A (es)
WO (1) WO2015002703A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
WO2014066318A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3104853B1 (en) 2014-02-10 2019-10-02 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CN114042061A (zh) * 2015-11-19 2022-02-15 通用医院有限公司 包含色甘酸的组合物在制备用于治疗非遗忘性轻度认知障碍的药物中的用途
CN108472275A (zh) * 2015-11-23 2018-08-31 阿尔茨治疗方法公司 治疗缺血性中风的组合物及方法
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
US20190240194A1 (en) * 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
WO2018067341A1 (en) * 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
WO2018071427A1 (en) * 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
CN111315363B (zh) 2017-09-22 2022-10-11 奥迪托皮克股份有限公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3084593A1 (en) * 2017-12-04 2019-06-13 The General Hospital Corporation Cromolyn compositions and methods thereof
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
WO2020051322A1 (en) * 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
SG11202106117SA (en) * 2018-12-10 2021-07-29 Massachusetts Gen Hospital Cromolyn esters and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470154B1 (en) * 1989-04-28 1996-06-05 Riker Laboratories, Inc. Dry powder inhalation device
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5989396A (en) 1997-04-02 1999-11-23 Eltech Systems Corporation Electrode and electrolytic cell containing same
SK285068B6 (sk) * 1997-09-29 2006-05-04 Nektar Therapeutics Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
US20040223918A1 (en) * 2003-05-07 2004-11-11 Chrysalis Technologies Incorporated Aerosolization of cromolyn sodium using a capillary aerosol generator
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
JP5731406B2 (ja) * 2009-01-29 2015-06-10 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体、クロモリン誘導体を用いた治療方法及び造影方法
PL2248517T3 (pl) * 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2014066318A1 (en) * 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
JP2019073921A (ja) * 2017-10-17 2019-05-16 アイシン精機株式会社 車両用ドアチェック装置

Also Published As

Publication number Publication date
AU2017254974A1 (en) 2017-11-23
AU2022200260A1 (en) 2022-02-10
AU2014284656B2 (en) 2017-11-23
AU2019271898B2 (en) 2022-02-03
AU2019271898C1 (en) 2022-06-09
CN110652495A (zh) 2020-01-07
EP2999337A4 (en) 2017-03-15
US9861608B2 (en) 2018-01-09
JP2021181493A (ja) 2021-11-25
HK1218050A1 (zh) 2017-02-03
CA2913235A1 (en) 2015-01-08
EP2999337A1 (en) 2016-03-30
JP2016534976A (ja) 2016-11-10
AU2019271898A1 (en) 2019-12-19
AU2014284656A1 (en) 2016-01-21
CA2913235C (en) 2021-07-13
CN105377037A (zh) 2016-03-02
JP2019112468A (ja) 2019-07-11
MX2020013362A (es) 2021-03-09
AU2014284656A2 (en) 2016-01-21
US20160106704A1 (en) 2016-04-21
WO2015002703A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
MX2020013362A (es) Metodos para la liberacion de cromolina.
IL268340A (en) Glucosylceramide synthase inhibitors for the treatment of diseases
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
HK1212248A1 (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma metvegfr ret
HK1220418A1 (zh) 治療呼吸系統疾病的方法及為此而製的製劑
HK1217439A1 (zh) 與毒性醛相關的疾病和治療
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
EA201500314A1 (ru) Лекарственные формы энзалутамида
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
HK1224184A1 (zh) 用於治療炎性疾病的化合物、藥物組合物和方法
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
ZA201603098B (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
MX2020005615A (es) Composiciones de cromolín y métodos de las mismas.
TH148448B (th) วิธีการสำหรับการบำบัดแก๊สปล่อย
LT2922541T (lt) Piridilo hidrazonai, skirti tuberkuliozės ir susijusių ligų gydymui
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний
UA88266U (ru) Способ комплексной профилактики и лечения поражений слизистой оболочки полости рта на фоне химиотерапии
GB201302884D0 (en) Novel methods for diagnosis and therapy
UA75671U (uk) Спосіб ступеневої інгаляційної терапії бронхолегеневої дисплазії у новонароджених
AU2013900493A0 (en) Breathable Electrodes and Methods of Manufacture